Fine needle aspiration biopsy of an osteoclast-rich undifferentiated urothelial carcinoma: A cytology case report and review of the literature

Purohit, Chetna; Hakam, Ardeshir

doi:10.4103/1742-6413.70407

Cited by 5 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tumor is called a "soft tissue giant cell tumor of low malignant potential" in soft tissue, and is a known entity that presents no obvious diagnostic problems [70,71]. However, tumors with GCTB-like histology are also seen in several parencymatous organs such as the ovary, urinary bladder, breast, extrabiliary system, and especially the pancreas [72][73][74][75][76]. Although they are seen as "de novo" in the parenchymatous organs, the tumors are mostly accompanied by benign epithelial, borderline/low-grade, or invasive carcinomas of these organs, which causes challenges regarding their diagnosis, nature, and nomenclature.…”

Section: Giant Cell Tumor Of the Bone-like Histology In Parenchymatous Organs (De Novo Or Accompanied Benign Borderline/low-grade Epithelmentioning

confidence: 99%

“…"De novo" GCTB-like lesions show clinical, histological, and immunohistochemical characteristics (epithelial markers are generally negative) similar to those of primary GCTB, and surgical resection is generally curative [75,[77][78][79][80][81]. Although very rare, malignant GCTB-like tumors with no epithelial differentiation have been reported, and the prognosis of these cases is poor [80].…”

Section: Giant Cell Tumor Of the Bone-like Histology In Parenchymatous Organs (De Novo Or Accompanied Benign Borderline/low-grade Epithelmentioning

confidence: 99%

See 1 more Smart Citation

Osteoclasts in Tumor Biology: Metastasis and Epithelial-Mesenchymal-Myeloid Transition

Behzatoğlu

2021

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Osteoclast is a specialized cell that originates from monocytic lineage, communicates closely with osteoblasts under physiological conditions, participates in bone modeling and re-modeling, contributes to calcium homeostasis and osteoimmunity. In pathological conditions, it is involved in many tumors such as giant cell bone tumor (osteoclastoma), aneurysmal bone cyst, osteosarcoma, and metastatic cancers, and it usually causes local spread and progression of the tumor, working against the host. Since osteoclasts play an active role in primary bone tumors and bone metastases, the use of anti-osteoclastic agents significantly reduces the mortality and morbidity rates of patients by preventing the progression and local spread of tumors. Osteoclasts also accompany undifferentiated carcinomas of many organs, especially pancreas, thyroid, bladder and ovary. Undifferentiated carcinomas rich in osteoclasts have osteoclastoma-like histology. In these organs, osteoclastoma-like histology may accompany epithelial carcinomas, and de novo, benign and borderline tumors. Mature and immature myeloid cells, including osteoclasts, play an active role in the tumor progression in primary and metastatic tumor microenvironment, in epithelial-mesenchymal transition (EMT), mesenchymal-epithelial-transition (MET), and cancer stem cell formation. Additionally, they are the most suitable candidates for cancer cells in cell fusion due to their evolutionary fusion capabilities. Myeloid features and markers (CD163, CD33, CD68 etc.) can be seen in metastatic cancer cells. Consequently, they provide metastatic cancer cells with motility, margination, transmigration, chemotaxis, phagocytosis, angiogenesis, matrix degradation, and resistance to chemotherapy. For these reasons, we think that the concept of Epithelial-Mesencyhmal-Myeloid-Transition (EMMT) will be more accurate than EMT for cancer cells with myeloid properties.

show abstract

Section: Giant Cell Tumor Of the Bone-like Histology In Parenchymatous Organs (De Novo Or Accompanied Benign Borderline/low-grade Epithelmentioning

confidence: 99%

Section: Giant Cell Tumor Of the Bone-like Histology In Parenchymatous Organs (De Novo Or Accompanied Benign Borderline/low-grade Epithelmentioning

confidence: 99%

Osteoclasts in Tumor Biology: Metastasis and Epithelial-Mesenchymal-Myeloid Transition

Behzatoğlu

2021

Pathol. Oncol. Res.

View full text Add to dashboard Cite

show abstract

“…Urinary bladder cancer is a prevalent malignancy that affects the urinary system, with nearly 98% of malignant bladder tumors originating from epithelial tissue [1]. Among these tumors, around 90% are categorized as urothelial carcinomas (UC) [2].…”

Section: Introductionmentioning

confidence: 99%

Expression of Gata Binding Protein 3 as a Prognostic Factor in Urogenital Lesions and Its Association With Morphology

Govardhan,

Mohapatra,

Naik

et al. 2023

Cureus

View full text Add to dashboard Cite

Background: Urogenital malignancies, encompassing urinary bladder cancer, prostate cancer, and renal cell carcinoma, pose significant diagnostic challenges due to overlapping histopathological features. GATA binding protein 3 (GATA3), a transcription factor associated with urothelial tissue, has shown promise as a potential diagnostic marker. This study aimed to investigate the incidence of these malignancies, explore GATA3's involvement in urothelial cancer (UC), and determine its role in distinguishing urogenital malignancies.Materials and methods: A cross-sectional, retro-prospective, hospital-based study was conducted from May 2019 to April 2021. The surgical samples of patients who underwent transurethral resection of bladder tumour (TURBT), transurethral resection of the prostate (TURP), radical cystoprostatectomy, total and partial radical nephrectomy specimens during the study period were reviewed. Patients diagnosed with urinary bladder neoplasm and high-grade prostate neoplasm along with chromophobe, oncocytic, sarcomatoid variant and clear cell carcinoma, renal cell carcinoma were included. Immunohistochemical analysis of GATA3 expression was performed, with scoring based on nuclear staining intensity and percentage of tumor cells labeled.Results: The study included 64 patients, predominantly males over 60 years. Personal habits revealed a high prevalence of smoking (85.9%). The most prevalent symptom was hematuria (75.0%), followed by hematuria with urgency (20.3%). The most common site of lesion was posterolateral (31.3%). Urothelial cancer was the most common malignancy, primarily high-grade. Strong positive GATA3 expression was significantly associated with high-grade UC (p=0.01) and invasion (p=0.01). However, low-grade UC and papillary urothelial neoplasm of low malignant potential exhibited moderate GATA3 expression. GATA3 demonstrated potential for distinguishing UC from other histological types.Conclusion: GATA3 expression correlates with high-grade urothelial cancer and invasive behavior, suggesting its utility as a diagnostic marker in challenging cases.

show abstract

“…The 2012 IF for CytoJournal was calculated based on citations from 2010[11121314151617181920212223242526272829303132333435363738] to 2011[3940414243444546474849505152535455565758596061] CytoJournal publications within the articles from indexed journals published in 2012. [1] Considering the trend over 5 years (2008-2012), CytoJournal's IF of 1.2 for 2012 is comparable with the other peer reviewed cytopathology journals [Table 1 and Figure 2].…”

mentioning

confidence: 99%

Announcement of first time Cytojournal impact factor for 2012 coincides with Cytojournal decade celebration (2004-2013)

Shidham

DeMay

2013

CytoJournal

View full text Add to dashboard Cite

Fine needle aspiration biopsy of an osteoclast-rich undifferentiated urothelial carcinoma: A cytology case report and review of the literature

Cited by 5 publications

References 20 publications

Osteoclasts in Tumor Biology: Metastasis and Epithelial-Mesenchymal-Myeloid Transition

Osteoclasts in Tumor Biology: Metastasis and Epithelial-Mesenchymal-Myeloid Transition

Expression of Gata Binding Protein 3 as a Prognostic Factor in Urogenital Lesions and Its Association With Morphology

Announcement of first time Cytojournal impact factor for 2012 coincides with Cytojournal decade celebration (2004-2013)

Contact Info

Product

Resources

About